BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19675582)

  • 1. A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis.
    Heckmann JM; Uwimpuhwe H; Ballo R; Kaur M; Bajic VB; Prince S
    Genes Immun; 2010 Jan; 11(1):1-10. PubMed ID: 19675582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of prednisone and steroid-sparing agents on decay accelerating factor (CD55) expression: implications in myasthenia gravis.
    Auret J; Abrahams A; Prince S; Heckmann JM
    Neuromuscul Disord; 2014 Jun; 24(6):499-508. PubMed ID: 24703255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The African-387 C>T TGFB1 variant is functional and associates with the ophthalmoplegic complication in juvenile myasthenia gravis.
    Nel M; Buys JM; Rautenbach R; Mowla S; Prince S; Heckmann JM
    J Hum Genet; 2016 Apr; 61(4):307-16. PubMed ID: 26632886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1.
    Cauvi DM; Cauvi G; Pollard KM
    J Immunol; 2006 Sep; 177(6):3837-47. PubMed ID: 16951346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
    Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
    Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor.
    Molina H; Miwa T; Zhou L; Hilliard B; Mastellos D; Maldonado MA; Lambris JD; Song WC
    Blood; 2002 Dec; 100(13):4544-9. PubMed ID: 12393518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells.
    Andoh A; Kinoshita K; Rosenberg I; Podolsky DK
    J Immunol; 2001 Oct; 167(7):3887-93. PubMed ID: 11564806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delta-short consensus repeat 4-decay accelerating factor (DAF: CD55) inhibits complement-mediated cytolysis but not NK cell-mediated cytolysis.
    Miyagawa S; Kubo T; Matsunami K; Kusama T; Beppu K; Nozaki H; Moritan T; Ahn C; Kim JY; Fukuta D; Shirakura R
    J Immunol; 2004 Sep; 173(6):3945-52. PubMed ID: 15356143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between decay-accelerating factor polymorphisms and allergic respiratory diseases.
    Kawai T; Takeshita S; Imoto Y; Matsumoto Y; Sakashita M; Suzuki D; Shibasaki M; Tamari M; Hirota T; Arinami T; Fujieda S; Noguchi E
    Clin Exp Allergy; 2009 Oct; 39(10):1508-14. PubMed ID: 19681921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.
    Hatanaka M; Seya T; Matsumoto M; Hara T; Nonaka M; Inoue N; Takeda J; Shimizu A
    Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):969-76. PubMed ID: 8615796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the active sites in decay-accelerating factor.
    Kuttner-Kondo LA; Mitchell L; Hourcade DE; Medof ME
    J Immunol; 2001 Aug; 167(4):2164-71. PubMed ID: 11490001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of transcription factor Sp1 and RNA binding protein HuR in the downregulation of Dr+ Escherichia coli receptor protein decay accelerating factor (DAF or CD55) by nitric oxide.
    Banadakoppa M; Liebenthal D; Nowak DE; Urvil P; Yallampalli U; Wilson GM; Kishor A; Yallampalli C
    FEBS J; 2013 Feb; 280(3):840-54. PubMed ID: 23176121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pigs express multiple forms of decay-accelerating factor (CD55), all of which contain only three short consensus repeats.
    Pérez de la Lastra JM; Harris CL; Hinchliffe SJ; Holt DS; Rushmere NK; Morgan BP
    J Immunol; 2000 Sep; 165(5):2563-73. PubMed ID: 10946283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury.
    Mason JC; Ahmed Z; Mankoff R; Lidington EA; Ahmad S; Bhatia V; Kinderlerer A; Randi AM; Haskard DO
    Circ Res; 2002 Oct; 91(8):696-703. PubMed ID: 12386146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of decay-accelerating factor expression and alpha1,3-galactosyltransferase knockout affords added protection from human complement-mediated injury.
    van Denderen BJ; Salvaris E; Romanella M; Aminian A; Katerelos M; Tange MJ; Pearse MJ; d'Apice AJ
    Transplantation; 1997 Sep; 64(6):882-8. PubMed ID: 9326415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.
    Song C; Xu Z; Miao J; Xu J; Wu X; Zhang F; Lin H; Li Z; Kaminski HJ
    Muscle Nerve; 2012 May; 45(5):668-675. PubMed ID: 22499093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury.
    Lidington EA; Haskard DO; Mason JC
    Blood; 2000 Oct; 96(8):2784-92. PubMed ID: 11023512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells.
    Andoh A; Shimada M; Araki Y; Fujiyama Y; Bamba T
    Cancer Immunol Immunother; 2002 Feb; 50(12):663-72. PubMed ID: 11862418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement associated pathogenic mechanisms in myasthenia gravis.
    Tüzün E; Christadoss P
    Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis.
    Sogabe H; Nangaku M; Ishibashi Y; Wada T; Fujita T; Sun X; Miwa T; Madaio MP; Song WC
    J Immunol; 2001 Sep; 167(5):2791-7. PubMed ID: 11509624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.